Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10073061 | 0.95 | POLB (0.65) | POLBKMT2ALMNANPC1ALDH1A1 | |
| SCHEMBL10073084 | 0.92 | POLB (0.76) | POLBKMT2ALMNANPC1ALDH1A1 | |
| SCHEMBL10073079 | 0.91 | POLB (0.64) | POLBKMT2ALMNANPC1ALDH1A1 | |
| SCHEMBL557635 | 0.88 | POLB (0.59) | POLBKMT2ALMNANPC1ALDH1A1 | |
| SCHEMBL10073081 | 0.87 | POLB (0.60) | POLBKMT2ALMNANPC1ALDH1A1 | |
| SCHEMBL10073082 | 0.86 | POLB (0.58) | POLBKMT2ALMNANPC1ALDH1A1 | |
| SCHEMBL10073119 | 0.85 | POLB (0.57) | POLBKMT2ALMNANPC1ALDH1A1 | |
| SCHEMBL10073080 | 0.82 | POLB (0.55) | POLBKMT2ALMNANPC1ALDH1A1 | |
| SCHEMBL10073074 | 0.80 | LMNA (0.67) | KMT2ALMNANPC1ALDH1A1MEN1 | |
| SCHEMBL10073065 | 0.75 | LMNA (0.69) | KMT2ALMNANPC1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012536-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-10 | — | — | US | disclosed |
| US-20120035179-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-02-09 | — | — | US | disclosed |
| US-20120035179-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-02-09 | — | — | US | disclosed |
| US-20100125090-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100125090-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-20 | — | — | US | disclosed |
| US-7598412-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598412-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012536-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | ABCB11, ABCB1, ABCC5 | POLB 1098/4885KMT2A 4175/4885LMNA 1873/4885 |
| US-20100125090-A1 | Modulators of ATP-Binding Cassette Transporters | ABCB11, ABCB1, ABCC5 | POLB 1098/4885KMT2A 4175/4885LMNA 1873/4885 |
| US-20120035179-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | ABCB11, ABCB1, ABCC5 | POLB 1098/4885KMT2A 4175/4885LMNA 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.